about
G-protein coupled receptor expression patterns delineate medulloblastoma subgroupsTwo-career families: published data and personal reflections.Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children.The survivin:Fas ratio is predictive of recurrent disease in neuroblastoma.Pancreastatin predicts survival in neuroendocrine tumors.90Y-edotreotide for metastatic carcinoid refractory to octreotide.MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use.Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumorsThe role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancerVPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptorsUtility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors."Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumorsNeuroendocrine tumors in children and young adults: rare or not so rare.Management of neuroendocrine tumors in children, adolescents, and young adults.2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells.VIP receptor 1 (VPAC1) promoter targets the expression of a reporter gene to cerebellum and adrenal medulla in transgenic mice.Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.Erratum to: VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.GIPR expression in gastric and duodenal neuroendocrine tumors.Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide.Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.Age-dependent levels of plasma neuropeptides in normal children.A multi-tyrosinated sst1/2 receptor preferring somatostatin agonist inhibits reflex and immune-mediated secretion in the guinea pig colon.Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells.
P50
Q28302285-824DE8B1-F4F3-4A9D-BCE3-EC9764AF942DQ30886395-B8F8B1C6-5786-4828-A071-93DDCD3C7A5FQ31160520-1F5F7623-902A-407C-ABCD-F448167F4F0AQ32065047-EAA1F4AB-9933-4649-AE33-062FA29369E8Q34016884-D6AB0A7E-BA80-4E51-A484-BA298BC0CEE3Q34101554-48042536-B4A7-4109-922B-3E89E9E35C0CQ34384839-D1920307-410E-4624-BB3C-A08A0DB0DBC9Q34546925-10088176-6690-4653-975E-E34517F2F226Q34610406-66B1F027-031D-46FB-9B65-2D02917A663CQ34680094-E0ECE15E-9F8A-4277-A022-2537D82AE99DQ34802364-45A4C5A8-6019-41CC-93D8-FCE4598A4882Q36164034-4DADBB5F-4F54-4C85-903C-CA899E2F947CQ37054934-0D555DBF-0014-4A11-9378-AE1EFDDFAF92Q37122608-3C51E3FA-4FF4-4D8C-AD78-45B9598D63E6Q37151615-13CB6824-AF3B-4EB3-832E-4910C4047D33Q37237829-E41FC9D7-213E-498F-AD1F-42B9192926A5Q37496864-F963312C-1E26-4A62-A72D-24DDC9E6CF56Q37504159-7EA2A375-DF7F-4E79-9821-F66B173F9134Q37694773-0F542C4C-D3AA-4378-B220-CF388355DD1CQ37846917-78F5FFC1-903E-4163-9BFA-C93E8BF838CEQ38004695-C162A5E9-3BAD-4288-A5FC-FD22B3FB6C5AQ39096682-83A57E71-C288-4846-BCD9-DB3AC34C0329Q40619794-D6C7C9BD-86D1-4112-BD4A-7869F5008926Q41635330-2647AA6E-0220-40FF-9FBE-D289F698EE21Q41851778-BE4AEE38-A574-48A8-82E2-41093681C6E8Q42342689-31859D6E-8D17-4107-882A-34E4B69164C0Q42734654-D29C0BBC-AA42-43E2-9D2F-28D0F7CFD255Q43636534-4A3320DC-12AA-43AC-BE00-284D88BC72A4Q44200148-BF70C875-58BB-4F02-8394-326524BB9051Q44200153-575CC837-DE15-485B-B996-18B693D495CEQ44451615-1C7003E3-2A18-495A-9BE5-972030BB7696Q45068998-4509C606-3AB9-4A8C-9F6F-EAAD96B440AA
P50
description
onderzoeker
@nl
name
Sue O'Dorisio
@ast
Sue O'Dorisio
@en
Sue O'Dorisio
@es
Sue O'Dorisio
@nl
Sue O'Dorisio
@sl
type
label
Sue O'Dorisio
@ast
Sue O'Dorisio
@en
Sue O'Dorisio
@es
Sue O'Dorisio
@nl
Sue O'Dorisio
@sl
altLabel
M Sue O'Dorisio
@en
M. Sue O'Dorisio
@en
prefLabel
Sue O'Dorisio
@ast
Sue O'Dorisio
@en
Sue O'Dorisio
@es
Sue O'Dorisio
@nl
Sue O'Dorisio
@sl